Drug Repurposing for COVID-19
Dr. Jean Bourbeau is leading a new Phase III clinical trial with dapson to target lung inflammation caused by COVID-19
View posts, news, and publications related to this research theme below.
Dr. Jean Bourbeau is leading a new Phase III clinical trial with dapson to target lung inflammation caused by COVID-19
Dr. Peter Goldberg receives an Innovation grant to build a clinical-grade ventilator that can be produced cheaply and easily
Dr. Dick Menzie’s team of PDFs contributed to a study in the Lancet on HIV and TB medications
Dr. Goldberg in La Presse – COVID-19 patients’ experiences post-ICU: enduring side effects and a long recovery.
Dr. Carolyn Baglole received a CIHR catalyst grant from the recent Health Effects of Vaping competition
Dr. Maziar Divangahi asserts that only a team effort across scientific disciplines will lead to the elimination of SARS-CoV-2.
Dr. Menzies was awarded the Canada Research Chair in Tuberculosis, Tier 1, in the Spring 2019 round.
Thanks to Adomo Donovan and the ICU Bridge Program, the MUHC’s ICU staff are now recognizable despite their PPE.
Dr. Menzies’ study found that 4-months of rifampin is a better course of treatment and more cost-effective for latent TB.
A new clinical trial, designed by Drs. Ezer, Martin, Benedetti & Smith, will test ciclesonide in the early stages of COVID-19.